Work

Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.4_suppl.111

Authors: Johanna C. Bendell, Janet E. Murphy, Devalingam Mahalingam, Balazs Halmos, Cynthia A. Sirard, Steven B. Landau, David P. Ryan

Institutions: Sarah Cannon, Tennessee Oncology, Massachusetts General Hospital, The University of Texas at San Antonio Health Science Center, Columbia University Irving Medical Center, Cambridge Intellectual Property (United Kingdom), Innovative Technology and Science (United Kingdom)

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589343364

Cites:

Cited by: 19

Related to: 10